The idea of blocking Tim-3-Tim-3L in conjunction with PD-1-PD-L1 blockade to correct tumour-induced T cell depletion/dysfunction in patients with advanced melanoma was further supported by this study. This evidence concerns the gene HAVCR2 and neoplasm.